Compare iShares China Large-Cap ETF (FXI) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares China Large-Cap ETF vs Merck & Co., Inc. — how do they compare? iShares China Large-Cap ETF trades at $35.2, while Merck & Co., Inc. trades at $133.6 (market cap $321.77B). The key difference: Merck & Co., Inc. pays a 2.61% dividend while iShares China Large-Cap ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, iShares China Large-Cap ETF nearer its low. Which is the better fit depends on your goals.
| FXI | MRK | |
|---|---|---|
52-Week High | $41.75 | $131.84 |
52-Week Low | $31.59 | $77.60 |
Market Cap | — | $321.77B |
Sector | — | Health |
Enterprise Value | — | $368.53B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FXI, the iShares China Large-Cap ETF, trades at $35.205, down 3.52% amid broader pressure on Chinese equities. Technical indicators show a bullish overall signal with strong moving average support, though oscillators are neutral. Recent news highlights China's export strength and AI-driven manufacturing rebound, while the ETF offers exposure to state-backed economic initiatives and upcoming dividend payments.
The outlook for FXI hinges on China's economic stabilization efforts and global demand for tech exports. Investment opportunities include diversification from US markets and exposure to AI hardware growth, but risks include US-China tensions, regulatory uncertainty, and value trap potential in Chinese equities.
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
